ACT Brief: AI Expands Global Site Leadership as Ozempic Shows Potential to Reverse Biological Age

In today’s ACT Brief, we examine how artificial intelligence is helping uncover site leaders in underserved regions to strengthen trial diversity—and explore new research suggesting Ozempic may reduce biological age by more than three years.